These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15294262)

  • 1. Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation.
    Chandra P; Rosen TS; Yeom ZH; Lee K; Kim HY; Danilo P; Rosen MR
    Europace; 2004 Sep; 6(5):384-91. PubMed ID: 15294262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of I
    Juhász V; Hornyik T; Benák A; Nagy N; Husti Z; Pap R; Sághy L; Virág L; Varró A; Baczkó I
    Can J Physiol Pharmacol; 2018 Jan; 96(1):18-25. PubMed ID: 28892643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter.
    Rahme MM; Ungab GA; Wadhwa M; Al-Kandari F; Yao B; Gupta A; Lee K; Kim HY; Feld GK
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):297-306. PubMed ID: 11584336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKr-blocker dofetilide.
    Hashimoto N; Yamashita T; Tsuruzoe N
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):162-9. PubMed ID: 18287884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation.
    Li D; Bénardeau A; Nattel S
    Circulation; 2000 Jul; 102(1):104-12. PubMed ID: 10880422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs.
    Yamamoto W; Hashimoto N; Matsuura J; Machida T; Ogino Y; Kobayashi T; Yamanaka Y; Ishiwata N; Yamashita T; Tanimoto K; Miyoshi S; Fukuda K; Nakaya H; Ogawa S
    J Cardiovasc Pharmacol; 2014 May; 63(5):421-7. PubMed ID: 24805146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.
    Liu G; Xue X; Gao C; Huang J; Qi D; Zhang Y; Dong JZ; Ma CS; Yan GX
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
    Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
    Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat.
    Blaauw Y; Gögelein H; Tieleman RG; van Hunnik A; Schotten U; Allessie MA
    Circulation; 2004 Sep; 110(13):1717-24. PubMed ID: 15364815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.
    Burashnikov A; Belardinelli L; Antzelevitch C
    J Pharmacol Exp Ther; 2012 Jan; 340(1):161-8. PubMed ID: 22005044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
    Nattel S; Liu L; St-Georges D
    Cardiovasc Res; 1998 Mar; 37(3):627-35. PubMed ID: 9659446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.
    Burashnikov A; Belardinelli L; Antzelevitch C
    Heart Rhythm; 2015 Apr; 12(4):836-44. PubMed ID: 25546810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
    Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapericardial ibutilide administration fails to terminate pacing-induced sustained atrial fibrillation in dogs.
    Vereckei A; Gorski JC; Ujhelyi M; Mehra R; Zipes DP
    Cardiovasc Drugs Ther; 2004 Jul; 18(4):269-77. PubMed ID: 15367824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Late Sodium Current Contributes to the Electrophysiological Effects of Chronic, but Not Acute, Dofetilide Administration.
    Qiu XS; Chauveau S; Anyukhovsky EP; Rahim T; Jiang YP; Harleton E; Feinmark SJ; Lin RZ; Coronel R; Janse MJ; Opthof T; Rosen TS; Cohen IS; Rosen MR
    Circ Arrhythm Electrophysiol; 2016 Apr; 9(4):e003655. PubMed ID: 27071826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.
    Aguilar-Shardonofsky M; Vigmond EJ; Nattel S; Comtois P
    Biophys J; 2012 Mar; 102(5):951-60. PubMed ID: 22404917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation.
    Coleman CI; Sood N; Chawla D; Talati R; Ghatak A; Kluger J;
    Europace; 2009 Jul; 11(7):892-5. PubMed ID: 19351630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN
    Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Perspectives and limitations in the treatment of vagus-induced atrial fibrillation. Insights from cellular pharmacology].
    Brandts B; Van Bracht M; Dirkmann D; Borchard R; Wickenbrock I; Prull MW; Meine M; Trappe HJ
    Med Klin (Munich); 2004 Jul; 99(7):341-6. PubMed ID: 15322712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential recovery of action potential duration and HERG currents from the effects of two methanesulfonamide class III antiarrhythmic agents, KCB-328 and dofetilide.
    Lee K; Park JB; Jeon BH; Kim KJ; Ryu PD; Kwon LS; Kim HY
    J Cardiovasc Pharmacol; 2003 Nov; 42(5):648-55. PubMed ID: 14576514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.